Study On The Active Components Of Anti - Lewis Lung Cancer Of Yi People 's "Huang Yao"

Blumea balsamifera DC. is a dry herb which is bitter cold and is taken by the lung and spleen channels. It has the efficacy of heat-clearing and detoxifying, resolving phlegm and removing blood stasis, it is characteristic drug treating lung cancer in Yi nationality. Huangyao has been proved effevtive on the basis of previous topics and also been found active components in it, but didn’t find effevtive active group. In this paper by LCMS-IT-TOF we analyze the difference between the original drug sample components and metabolites and serum samples between treatment group useing active component theory, advantages of metabolomics and sophisticated analysis of vivo component associated group, to determine the potential of the active component and metabolites, analyze anticancer active components.First, Huangyao is identified by DNA barcoding. Active components of Huangyao in dichloromethane are enriched, mices are given part Ⅶ which are separated by gavage. Experiments use C57BL/6J mice, inject lung cancer cells to the right axillary subcutaneously, the successful tumor-bearing mices are divided into eight groups in random, n=13, model group, high dosage, middle dosage and low dosage group of parts Ⅶ, Xanthoxylin group, Paclitaxol group, control group, middle dosage of normal. During administration we observe the survial station of mice, monitor the change of tumor volume, acess feces and urine of mice within two hours after administration, after 19 days, take the eyeball for blood and take tumor tissue, spleen, thymus with the conventional method, then weight them, calculate their tumor inhibitory rate, spleen index and Thymus--index. Study Pathological change of tumor tissues by HE, detect the protein expression of VEGF and TNF-α by IHC-P. The serum urine and feces are analyzed by LCMS-IT-TOF, identify the active component through combining with standard component, analyzing the same nucleus skeleton and the molecular characteristics of the cleavage fragments and searching database.The results show that (1) tumor weights of each treatment group are less than the model group (4.17 ± 1.08) g, the tumor weight of high dos--age group, Xanthoxylin group, Paclitaxol group are (2.67 ± 1.08) g, (3.2 7 ± 1.26) g, (3.20 ± 1.30) g, the differences are significant (P<0.05), the inhibition rates are 35.93%,21.6%.23.34%; The spleen Index of high dosage and low dosage group, Xanthoxylin group, Paclitaxol group are ( 11.64±1.96)、(11.58±2.42)、(11.78±3.12)、(11.86±1.94) mg/g, the differ--ences are significant compared with model group(P<0.05). (2) The averag--e optical density of VEGF protein in each treated group is significantly lower than model group (P<0.05).The high dosage group is significantly h--igher than Paclitaxol group (P<0.05). The average optical density of TNF-α protein in high dosage group, Xanthoxylin group, Paclitaxol group is s--ignificantly lower than model group (P<0.05). (3) The structures of 13 c--omponents were identifed by LCMS-IT-TOF from Huangyao, they are Di--hydroquercetin-4’-methylether(1); tamarixetin (2); 3,3’4’,5-tetrahydroxy-meth-oxyflavanone (3); Chrysoeriol(4); diosmetin(5); rhamnetin(6); 3,5,3’-tri hydroxy-7,4’-dimethoxyflavone(7); Dihydroquercetin-7,4’-dimer(8); Luteoli--n-7-methyl-ether(9); Blumeaguaianone B (10); 5,6,7,3’,4’,5’-hexadicflavone (11); 5-hydroxyl-3,1,3’,4’-tetramethoxyflavone(12); 5α,8α-epidioxyer--gosta-6,22-dien-3β-ol(13), anticancer active components and metabolites will be studed in the future.This article studied the anticancer active components and their metabolites using metabolomics on the base of previous work to provid theoretical basis for treatment of lung cancer.